Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy.
GR, V., AD, P., DA, R., & EA, C. (2026). Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy.. Science translational medicine. https://doi.org/10.1126/scitranslmed.aeg8772
GR V, AD P, DA R, EA C. Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy.. Science translational medicine. 2026; doi: 10.1126/scitranslmed.aeg8772
GR V, AD P, DA R, et al. Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy.[J]. Science translational medicine. 2026. DOI: 10.1126/scitranslmed.aeg8772.
@article{gr2026,
author = {Villa GR and Patel AD and Reardon DA and Chiocca EA},
title = {Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy.},
journal = {Science translational medicine},
year = {2026},
doi = {10.1126/scitranslmed.aeg8772},
note = {PMID: 42525786},
}
TY - JOUR AU - Villa GR AU - Patel AD AU - Reardon DA AU - Chiocca EA TI - Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy. T2 - Science translational medicine PY - 2026 DO - 10.1126/scitranslmed.aeg8772 AN - PMID:42525786 ER -
Glioblastoma remains the most aggressive primary malignant brain tumor in adults, with survival largely unchanged despite advances in molecular diagnostics and supportive care. Therapeutic failure reflects fundamental biological and anatomical barriers, including intratumoral heterogeneity, an immunosuppressive tumor microenvironment, and restricted drug delivery across the blood-brain barrier. In this Review, we summarize the current standard of care and critically examine emerging strategies aimed at overcoming these constraints, including locoregional delivery technologies, immunotherapy, biomarker-defined precision approaches, and adaptive clinical trial designs. We highlight key translational and clinical studies shaping the field and discuss principles for developing more effective, integrated therapeutic paradigms.